Sends email in progress
 

Remember me
Top news
Scientific news
Advantage of PET-Scan in the detection of occult cancers following an unprovoked VTE
Supportive care
Reviewed Article
Published online: 25 January 2016
Advantage of PET-Scan in the detection of occult cancers following an...
Dr Anne Roche (Hôpital Européen Georges-Pompidou - Paris)
Cancers associated with venous thromboembolism (VTE) are diverse, making the screening process long, invasive and expensive. Approximately 10% of patients are diagnosed with cancer in the year following an unprovoked VTE episode.
Detecting the disease at the time of the thromboembolic event would...
Read more
The use of low-dose immune globulin to prevent infection in hypogammaglobulinaemia patients increases the risk of serious arterial thromboembolic events
Supportive care
Reviewed Article
Published online: 25 January 2016
The use of low-dose immune globulin to prevent infection in...
Dr Benjamin Planquette (Hôpital Européen Georges-Pompidou - Paris)
Due to profound immunodeficiency, polyvalent intravenous immune globulins (IVIg) are administered to patients with chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM) to prevent the occurrence of infections, the leading cause of death in these patients.
In 2013, the FDA warned of the increased risk of arterial...
Read more
Ruxolitinib decreases the risk of thrombosis in patients with polycythemia vera and/or myelofibrosis: a meta-analysis
Supportive care
Reviewed Article
Published online: 4 January 2016
Ruxolitinib decreases the risk of thrombosis in patients with polycythemia vera...
Pr David Smadja (Hôpital Européen Georges-Pompidou - Paris)
Ruxolitinib (JAKAVI®), an antineoplastic agent, is a selective inhibitor of JAK1 and JAK2 (Janus kinases), enzymes involved in the signalling of various growth factors (including erythropoietin) and cytokines that are important in haematopoiesis and immune function.
JAKAVI® is indicated for the...
Read more
Leukemia
Report
Published online: 7 December 2015
EUTOS is the best long-term prognostic score for CML
Dr Philippe Quittet (Hôpital Lapeyronie - CHU de Montpellier)
The EUTOS register included data from patients with CML treated with imatinib (IM) in all clinical trials between 2002 and 2006. The new EUTOS long-term survival score (ELTS) was published in 2014 (Blood 2014; 124 (21):153). It identifies three risk groups in terms of survival in 2205 patients. This score was then validated in...
Read more
Leukemia
Report
Published online: 6 December 2015
Advantage of next generation sequencing (NGS) over conventional sequencing...
Pr Claude Preudhomme (CHRU de Lille)
The objective of this study was to compare 2 sequencing techniques (Sanger and NGS) for the detection of BCR-ABL mutations for patients with failure and warning to 1st- or 2nd-line tyrosine kinase inhibitor (TKI) therapy according to the 2013 ELN criteria.
Between May 2013 and June 2015, 298 patients met these criteria,...
Read more
Leukemia
Report
Published online: 5 December 2015
In CML, the OPTIM-Imatinib study shows that dose adjustment of imatinib by drug...
Dr Philippe Quittet (Hôpital Lapeyronie - CHU de Montpellier)
This study by the French CML group shows the importance of personalised treatment in CML patients in chronic phase (CML-CP) treated with first-line  imatinib (IM). This standard treatment is administered as a single dose 400 mg/d. An analysis of the IRIS study showed that the minimum serum rate (C) min> 1000 ng/mL was...
Read more
All scientific articles